Vaccination

A method for preventing herpes zoster (HZ) in a human individual for at least 4 years, comprising the steps of administering to the individual an immunogenic composition comprising:

• (a) a VZV gE antigen truncated to remove the carboxy terminal anchor region, and
• (b) an adjuvant comprising a saponin, a TLR-4 agonist and liposomes.

A method for preventing herpes zoster in an individual comprising the steps of:

• (a) selecting an individual from a population that is poorly protected by a live attenuated VZV composition, and,
• (b) administering a first and a second dose of an immunogenic composition comprising a VZV gE antigen truncated to remove the carboxy terminal anchor region, and an adjuvant comprising a saponin, a TLR-4 agonist and liposomes,
• wherein the prevention of HZ lasts for at least 4 years after administration of the second dose.

A method for reducing the incidence of HZ in a population of human individuals, comprising administering to each individual a first and a second dose of an immunogenic composition comprising a VZV gE antigen truncated to remove the carboxy terminal anchor region and an adjuvant comprising a saponin, a TLR-4 agonist and liposomes, wherein the occurrence of HZ is reduced by 60% or more in said population.